- Discuss pre-treatment Assessment, recommended regimens and on-treatment monitoring for simplified HCV treatment
- Discuss some real-world HCV treatment issues related to choice of direct-acting antiviral (DAA) therapy in HIV-HCV coinfected patients
- Identify relevant drug interactions of DAAs with antiretroviral therapy
This module takes a case-based approach to the pre-treatment assessment, treatment and monitoring of those with HIV-HCV coinfection.
Oluwaseun Falade-Nwulia, MBBS, MPH
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Dr. Falade-Nwulia is an Associate Professor at the Johns Hopkins University School of Medicine in Baltimore, MD. She completed her residency in internal medicine at the Johns Hopkins Bayview Medical center of the Johns Hopkins University School of Medicine and her fellowship in Infectious Diseases at the Johns Hopkins University School of Medicine. Her research has focused on understanding the distribution and impact of treatments for hepatitis and HIV infections on clinical outcomes for people who use drugs and improving access to HCV/HIV and drug use treatment for people who use drugs. She served as Medical Director of the Baltimore City Health Department Ryan White funded HIV Early Intervention Initiative program from 2012-2015 and also designed, implemented and directed the Baltimore City Health department HCV testing, linkage to care and treatment programs. She provides hepatitis, HIV care and medication assisted treatment including buprenorphine prescription at the Johns Hopkins Infectious Disease Clinic. She also served on the American Association for the Study of Liver Diseases (AASLD)/ Infectious Disease Society of America (IDSA) HCV Guidance Expert Panel from 2015 to 2020.
This accredited continuing education activity is provided by American Academy of CME, Inc.
The 16th Annual American Conference for the Treatment of HIV (ACTHIV 2021) was held May 5-7, 2022. The conference and this Best of ACTHIV web archive were supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck, Theratechnologies, and ViiV Healthcare.
Oluwaseun Falade-Nwulia, MBBS, MPH, Associate Professor, Johns Hopkins University School of Medicine
Estimated time to complete: 45 minutes
This activity is intended for frontline providers of care to persons at risk for or who are living with HIV, including specialist and primary care Physicians, NPs, PAs, Nurses, and Pharmacists. Other HIV care team members are also encouraged to participate.
American Academy of CME is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Academy of CME, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses Practitioners and Nurses:
American Academy of CME, Inc. designates this educational activity for 0.75 contact hours (0.5 pharmacotherapeutic contact hours).
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until September 15, 2023. PAs should only claim credit commensurate with the extent of their participation.
All other members of the HIV Care team will receive a certificate of participation.
HOW TO RECEIVE CREDIT
There is no fee to participate in this activity. To obtain your certificate of credit/participation, you must read the CME/CE information, review the activity content, and complete the activity assessment and evaluation. Upon submission, your CE certificate will be emailed to you within 24 hours.
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
The opinions expressed in this accredited continuing education activity are those of the faculty, and do not represent those of the Academy, or ACTHIV. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Off-Label Usage Disclosure
There will be no off-label/investigational uses discussed in this presentation.
Oluwaseun Falade-Nwulia, MBBS, MPH discloses the following relevant relationships with ineligible companies: advisory board/consultant with Gilead Sciences.
The following individuals have no relevant financial relationships with ineligible companies to disclose: Beatrice Aladin, MD, MPA; Jillian Baron, MD, MPH; John T Brooks, MD; Jose Castillo-Mancilla, MD; Lisa Catalli, MSN, NP-C; Jonathan Colasanti, MD, MSPH; Sherrillyn Crooks, PA-C; Christopher Evans, MD; Courtney V Fletcher, PharmD; Donna Futterman, MD; Rajesh Gandhi, MD; Mary Glenshaw, PhD, MPH, OTR/L; Jose Gutierrez, PhD, MSN, FNP-BC; Tomasz Jodlowski, PharmD; John JD Juchniewicz, MCIS, CHCP, FACEHP; Natalie Kirkwood, RN, BSN, JD; Jennifer Kay-Berene Klein, MSN; Harry Lampiris, MD; Sharon Lee, MD; Vincent Lo Re, MD, MSCE; Amber McCracken; Lorenzo McFarland, DHA, MPH, MSW, PMP; Paul Miniter, MS; Edward Moylan, RP; Asa Radix, MD, PhD, MPH; Dianne Rausch, PhD; Aaron Richterman, MD MPH; Jeri (Jieri) Sumitani, MMSc, PA-C; Pablo Tebas, MD; Ronald Dean Wilcox MD; Darcy Wooten, MD, MS
The following individuals have relevant financial relationships with ineligible companies to disclose:
Dawn Averitt, BIS: Advisory Board/Consultant – Merck, Gilead Sciences, ViiV Healthcare
Roger Bedimo, MD, MS: Advisory Board/Consultant – Merck, ViiV Healthcare, Theratechnologies*
Eric Daar, MD: Advisory Board/Consultant – Merck, Gilead Sciences, ViiV Healthcare; Grant/Research Support – Gilead Sciences, ViiV Healthcare
Carlos del Rio, MD: Advisory Board/Consultant: Resverolix, Sanofi-Pasteur*
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board/Consultant – ViiV Healthcare; Grant/Research Support – ViiV Healthcare; Speakers Bureau – Gilead Sciences, ViiV Healthcare
H. Nina Kim, MD, MSc: Grant/Research Support – Gilead Sciences
Igho Ofotokun, MD, MSc: Grant/Research Support – Merck
Tonia Poteat, PhD, MPH, PA-C: Advisory Board/Consultant – Merck, ViiV Healthcare
Jennifer Price, MD, PhD: Advisory Board/Consultant – Theratechnologies, Gilead Sciences, Merck; Grant/Research Support – Gilead Sciences, Merck; Speaker’s Bureau – Gilead Sciences
Jason Schafer, PharmD, MPH: Advisory Board/Consultant – Merck, ViiV Healthcare; Grant/Research Support – Merck, Gilead Sciences*
Renslow Sherer MD: Grant/Research Support – Gilead Sciences
William R Short, MD, MPH, FIDSA: Advisory Board/Consultant – Gilead Sciences, ViiV Healthcare; Speaker’s Bureau – ViiV Healthcare, Janssen
Babaafemi Taiwo, MBBS: Advisory Board/Consultant – Gilead Sciences, Merck, ViiV Healthcare, Janssen
Melanie Thompson, MD: Grant/Research Support – Cepheid Inc, Cytodyn Inc, Frontier Biotechnologies, Gilead Sciences, GlaxoSmithKline, Merck, ViiV Healthcare
Andrea Weddle, MSW: Policy Consultation: Merck
Susan Weiss, FNP-BC, MSN, AAHIVS: Advisory Board* – Gilead Sciences, Merck, ViiV Healthcare, Janssen; Speaker’s Bureau* – Gilead Sciences, ViiV Healthcare, Janssen
*Indicates relationship has ended
For questions related to CME/CE credit, contact CEservices@academycme.org
Hardware/Software Requirements To access this activity hardware and software requirements are noted below.
Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Copyright 2022 American Academy of CME, Inc.
- HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. https://www.HCVguidelines.org
- University of Liverpool Hepatits Drug Interactions Checker. https://www.hep-druginteractions.org/checker